DHP Korea and Dongwha enter agreement over Zabofloxacin

Published: 2008-04-07 06:57:00

Updated: 2008-04-07 06:57:00

DHP Korea and Dongwha Pharmaceutical has recently announced an agreement granting DHP exclusive rights to develop and commercialize Zabofloxacin (DW224a) in the field of ophthalmology.

DHP plans to develop Zabofloxacin for the treatment of ophthalmic diseases.

Zabofloxacin is a fluoroquinol...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK